• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

门诊环境中 HIV 感染者的食物摄入与达芦那韦血浆浓度。

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

机构信息

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.

University of Groningen, University Medical Center Groningen, Department of Dietetics, Groningen, The Netherlands.

出版信息

Br J Clin Pharmacol. 2017 Oct;83(10):2325-2329. doi: 10.1111/bcp.13366. Epub 2017 Aug 1.

DOI:10.1111/bcp.13366
PMID:28686287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5595942/
Abstract

AIMS

Patients receiving darunavir are advised to take it concomitantly with food. The objectives of the present cross-sectional study were to evaluate the actual concomitant food intake of patients visiting an HIV outpatient clinic.

METHODS

Sixty participants treated with darunavir/ritonavir once daily were subjected to a food recall questionnaire concerning their last concomitant food intake with darunavir. Darunavir trough concentrations were calculated.

RESULTS

The median food intake was 507 (0-2707) kcal; protein intake, 20 (0-221)g; carbohydrate intake, 62 (0-267)g; fat intake: 14 (0-143)g; and dietary fibre: 4 (0-30)g. Twenty-five patients (42%) ingested their drug with between-meal snacks. No relationship was found between food intake and trough concentrations.

CONCLUSIONS

Clear advice on the optimal caloric intake is needed, to avoid high caloric intake in patients who already have an increased risk of cardiovascular disease due to their HIV infection.

摘要

目的

接受达芦那韦治疗的患者被建议同时进食。本横断面研究的目的是评估在 HIV 门诊就诊的患者实际同时进食达芦那韦的情况。

方法

对 60 名每日接受一次达芦那韦/利托那韦治疗的患者进行了有关他们最近同时进食达芦那韦的食物回忆问卷调查。计算达芦那韦谷浓度。

结果

中位食物摄入量为 507(0-2707)千卡;蛋白质摄入量为 20(0-221)g;碳水化合物摄入量为 62(0-267)g;脂肪摄入量为 14(0-143)g;膳食纤维摄入量为 4(0-30)g。25 名患者(42%)在用餐之间吃零食时服药。食物摄入量与谷浓度之间没有相关性。

结论

需要就最佳热量摄入提供明确建议,以避免因 HIV 感染而使心血管疾病风险增加的患者摄入高热量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a53/5595942/052e534cbf07/BCP-83-2325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a53/5595942/052e534cbf07/BCP-83-2325-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a53/5595942/052e534cbf07/BCP-83-2325-g001.jpg

相似文献

1
Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.门诊环境中 HIV 感染者的食物摄入与达芦那韦血浆浓度。
Br J Clin Pharmacol. 2017 Oct;83(10):2325-2329. doi: 10.1111/bcp.13366. Epub 2017 Aug 1.
2
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.达芦那韦/利托那韦剂量减少(800/100 至 400/100mg 每日一次)的药代动力学模型,在含达芦那韦/利托那韦方案中对病毒学抑制的 HIV 感染患者:ANRS 165 DARULIGHT 子研究。
J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193.
3
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.联合应用雷迪帕韦可降低 HIV-1 感染患者的达芦那韦日暴露量。
Pharmacol Res. 2012 Feb;65(2):198-203. doi: 10.1016/j.phrs.2011.09.006. Epub 2011 Sep 20.
4
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.达芦那韦脑脊液浓度的决定因素:每日一次给药和药物遗传学的影响。
AIDS. 2012 Jul 31;26(12):1529-33. doi: 10.1097/QAD.0b013e3283553619.
5
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.达芦那韦/考比司他和依曲韦林单独及联合用于 HIV 感染患者的药代动力学。
J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.
6
Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.HIV-1 感染孕妇中达芦那韦的总浓度和游离浓度的药代动力学。
J Antimicrob Chemother. 2015 Feb;70(2):534-42. doi: 10.1093/jac/dku400. Epub 2014 Oct 17.
7
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.当使用考比司他与利托那韦增强时,HIV 感染者脑脊液中的达芦那韦浓度。
J Antimicrob Chemother. 2017 Sep 1;72(9):2574-2577. doi: 10.1093/jac/dkx165.
8
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.在接受过大量治疗的HIV感染患者中,以达芦那韦抑制商数为指导,将治疗简化为每日一次的达芦那韦/利托那韦治疗。
Antivir Ther. 2010;15(2):219-25. doi: 10.3851/IMP1519.
9
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.每日一次服用增强剂量达芦那韦的药代动力学和药效学
J Antimicrob Chemother. 2014 Oct;69(10):2591-605. doi: 10.1093/jac/dku193. Epub 2014 Jun 20.
10
Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.已批准的每日一次剂量的达芦那韦/利托那韦方案在 HIV 感染儿童中的药代动力学、短期安全性和疗效。
Pediatr Infect Dis J. 2018 Oct;37(10):1008-1010. doi: 10.1097/INF.0000000000001964.

引用本文的文献

1
Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.肥胖症手术对艾滋病毒感染者抗逆转录病毒药物药代动力学的影响。
Clin Pharmacokinet. 2022 May;61(5):619-635. doi: 10.1007/s40262-022-01120-7. Epub 2022 Apr 11.
2
Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis.抗逆转录病毒药物与食物和补充剂相互作用的药代动力学结果:系统评价和荟萃分析。
Nutrients. 2022 Jan 25;14(3):520. doi: 10.3390/nu14030520.
3
Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

本文引用的文献

1
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.《2016年IUPHAR/BPS药理学指南:迈向1300个蛋白质靶点与6000种配体之间的精准定量相互作用》
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
2
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.抗逆转录病毒治疗开始后的短期体重增加及随后患心血管疾病和糖尿病的风险:D:A:D研究
HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.
3
Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.
基于HIV门诊数据的达芦那韦群体药代动力学模型。
Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.
4
Risk factors contributing to a low darunavir plasma concentration.导致达芦那韦血浆浓度低的相关危险因素。
Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7.
关于HIV感染患者代谢紊乱与心血管风险的共识文件执行摘要。
Enferm Infecc Microbiol Clin. 2015 Jan;33(1):41-7. doi: 10.1016/j.eimc.2014.05.018. Epub 2014 Aug 3.
4
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.人群药代动力学模型研究及不同剂量方案下达芦那韦和利托那韦在 HIV 感染者中的应用评价。
J Antimicrob Chemother. 2014 Sep;69(9):2489-98. doi: 10.1093/jac/dku131. Epub 2014 May 12.
5
Cardiovascular disease in human immunodeficiency virus.人类免疫缺陷病毒相关的心血管疾病
Intern Med J. 2014 Apr;44(4):315-24. doi: 10.1111/imj.12381.
6
Influence of erroneous patient records on population pharmacokinetic modeling and individual bayesian estimation.错误患者记录对群体药代动力学建模和个体贝叶斯估计的影响。
Ther Drug Monit. 2012 Oct;34(5):526-34. doi: 10.1097/FTD.0b013e3182616937.
7
The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.治疗性 HIV 感染中糖尿病和血脂异常的负担及心脏代谢护理方法。
Curr HIV/AIDS Rep. 2012 Sep;9(3):206-17. doi: 10.1007/s11904-012-0124-x.
8
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.达芦那韦/利托那韦800/100毫克每日一次在初治和经治患者中的药代动力学、疗效及安全性
HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418.
9
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.初治的HIV-1感染患者在第48周时,每日一次服用达芦那韦/利托那韦与洛匹那韦/利托那韦的疗效和安全性比较。
AIDS. 2008 Jul 31;22(12):1389-97. doi: 10.1097/QAD.0b013e32830285fb.
10
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.不同餐食类型对达芦那韦(TMC114)/利托那韦在HIV阴性健康志愿者体内药代动力学的影响。
J Clin Pharmacol. 2007 Apr;47(4):479-84. doi: 10.1177/0091270006298603.